Cytrx Corp (NASDAQ:CYTR)

CAPS Rating: 2 out of 5

A biopharmaceutical research and development company engaged in developing human therapeutic products based primarily upon its small molecule molecular chaperone co-induction technology.

Recs

0
Player Avatar pchop123 (78.31) Submitted: 2/22/2013 1:33:21 PM : Outperform Start Price: $2.01 CYTR Score: +12.18

upward bias

Featured Broker Partners


Advertisement